Wieser R (Jul 2007). "The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions". Gene. 396 (2): 346–57. doi:10.1016/j.gene.2007.04.012. PMID17507183.
Buonamici S, Chakraborty S, Senyuk V, Nucifora G (2003). "The role of EVI1 in normal and leukemic cells". Blood Cells, Molecules & Diseases. 31 (2): 206–12. doi:10.1016/S1079-9796(03)00159-1. PMID12972028.
Liu Y, Chen L, Ko TC, Fields AP, Thompson EA (Jun 2006). "Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT". Oncogene. 25 (25): 3565–75. doi:10.1038/sj.onc.1209403. PMID16462766. S2CID27099061.
De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE (Dec 2007). "Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications". Trends in Immunology. 28 (12): 519–24. doi:10.1016/j.it.2007.09.004. PMID17981504.
Nucifora G, Laricchia-Robbio L, Senyuk V (Mar 2006). "EVI1 and hematopoietic disorders: history and perspectives". Gene. 368: 1–11. doi:10.1016/j.gene.2005.09.020. PMID16314052.
Haas K, Kundi M, Sperr WR, Esterbauer H, Ludwig WD, Ratei R, Koller E, Gruener H, Sauerland C, Fonatsch C, Valent P, Wieser R (Apr 2008). "Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration". Genes, Chromosomes & Cancer. 47 (4): 288–98. doi:10.1002/gcc.20532. PMID18181178. S2CID45500978.
Vinatzer U, Taplick J, Seiser C, Fonatsch C, Wieser R (Sep 2001). "The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase". British Journal of Haematology. 114 (3): 566–73. doi:10.1046/j.1365-2141.2001.02987.x. PMID11552981. S2CID7643309.
Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K, Hirai H (Jul 1998). "The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3". Nature. 394 (6688): 92–6. Bibcode:1998Natur.394...92K. doi:10.1038/27945. PMID9665135. S2CID4404132.
Wieser R (Jul 2007). "The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions". Gene. 396 (2): 346–57. doi:10.1016/j.gene.2007.04.012. PMID17507183.
Buonamici S, Chakraborty S, Senyuk V, Nucifora G (2003). "The role of EVI1 in normal and leukemic cells". Blood Cells, Molecules & Diseases. 31 (2): 206–12. doi:10.1016/S1079-9796(03)00159-1. PMID12972028.
Liu Y, Chen L, Ko TC, Fields AP, Thompson EA (Jun 2006). "Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT". Oncogene. 25 (25): 3565–75. doi:10.1038/sj.onc.1209403. PMID16462766. S2CID27099061.
De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE (Dec 2007). "Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications". Trends in Immunology. 28 (12): 519–24. doi:10.1016/j.it.2007.09.004. PMID17981504.
Nucifora G, Laricchia-Robbio L, Senyuk V (Mar 2006). "EVI1 and hematopoietic disorders: history and perspectives". Gene. 368: 1–11. doi:10.1016/j.gene.2005.09.020. PMID16314052.
Haas K, Kundi M, Sperr WR, Esterbauer H, Ludwig WD, Ratei R, Koller E, Gruener H, Sauerland C, Fonatsch C, Valent P, Wieser R (Apr 2008). "Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration". Genes, Chromosomes & Cancer. 47 (4): 288–98. doi:10.1002/gcc.20532. PMID18181178. S2CID45500978.
Vinatzer U, Taplick J, Seiser C, Fonatsch C, Wieser R (Sep 2001). "The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase". British Journal of Haematology. 114 (3): 566–73. doi:10.1046/j.1365-2141.2001.02987.x. PMID11552981. S2CID7643309.
Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K, Hirai H (Jul 1998). "The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3". Nature. 394 (6688): 92–6. Bibcode:1998Natur.394...92K. doi:10.1038/27945. PMID9665135. S2CID4404132.
ncbi.nlm.nih.gov
"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN (Sep 1988). "Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines". Cell. 54 (6): 831–40. doi:10.1016/S0092-8674(88)91175-0. PMID2842066. S2CID30211647.
Liu Y, Chen L, Ko TC, Fields AP, Thompson EA (Jun 2006). "Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT". Oncogene. 25 (25): 3565–75. doi:10.1038/sj.onc.1209403. PMID16462766. S2CID27099061.
Haas K, Kundi M, Sperr WR, Esterbauer H, Ludwig WD, Ratei R, Koller E, Gruener H, Sauerland C, Fonatsch C, Valent P, Wieser R (Apr 2008). "Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration". Genes, Chromosomes & Cancer. 47 (4): 288–98. doi:10.1002/gcc.20532. PMID18181178. S2CID45500978.
Vinatzer U, Taplick J, Seiser C, Fonatsch C, Wieser R (Sep 2001). "The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase". British Journal of Haematology. 114 (3): 566–73. doi:10.1046/j.1365-2141.2001.02987.x. PMID11552981. S2CID7643309.
Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K, Hirai H (Jul 1998). "The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3". Nature. 394 (6688): 92–6. Bibcode:1998Natur.394...92K. doi:10.1038/27945. PMID9665135. S2CID4404132.